Aeterna Zentaris Inc. - AEZS Net earnings per one share for the last twelve months

Aeterna Zentaris (AEZS) automates molecular bioscreening using AI and robotics, eliminating manual labor. The growth rate history of net income per share YoY ttm illustrates the commercialization of endocrinology tests and drugs. The value of -77.30 reflects the baseline level of the metric. Patent protection for orphan systems creates a powerful barrier for competitors, ensuring market exclusivity.
Aeterna Zentaris Inc. - analytical breakdowns and key metrics (AEZS)

The synergy of the updated development portfolio of Aeterna Zentaris (AEZS) requires confirmation through earnings per share efficiency. This metric measures the percentage change in EPS over a rolling year, revealing the actual business resilience between quarterly reports. It determines the extent to which the current financial trajectory is supported by fundamental revenue growth. By analyzing the EPS dynamics over the last 12 months YoY, an investor can see the company's margin of safety during the management's operational adaptation period.